Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $293000.0.

  • Ernexa Therapeutics' Share-based Compensation fell 2765.43% to $293000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 2337.25%. This contributed to the annual value of $1.5 million for FY2024, which is 2238.33% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Share-based Compensation of $293000.0 as of Q3 2025, which was down 2765.43% from $368000.0 recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Share-based Compensation peaked at $1.7 million during Q3 2021, and registered a low of $165000.0 during Q4 2023.
  • For the 5-year period, Ernexa Therapeutics' Share-based Compensation averaged around $564555.6, with its median value being $414500.0 (2021).
  • In the last 5 years, Ernexa Therapeutics' Share-based Compensation soared by 750534.88% in 2021 and then crashed by 7565.42% in 2023.
  • Over the past 5 years, Ernexa Therapeutics' Share-based Compensation (Quarter) stood at $1.7 million in 2021, then plummeted by 77.04% to $397000.0 in 2022, then tumbled by 58.44% to $165000.0 in 2023, then soared by 148.48% to $410000.0 in 2024, then decreased by 28.54% to $293000.0 in 2025.
  • Its Share-based Compensation was $293000.0 in Q3 2025, compared to $368000.0 in Q2 2025 and $502000.0 in Q1 2025.